Quick Comparison
| L-Carnitine | VK2735 | |
|---|---|---|
| Half-Life | 2-3 hours (injectable); oral bioavailability 15-25% | Approximately 144-168 hours (6-7 days), supporting once-weekly dosing |
| Typical Dosage | Oral: 500-2000 mg once or twice daily. Injectable: 500-1000 mg intramuscular two or three times weekly. Clinical (Carnitor): 50-100 mg/kg/day oral for primary carnitine deficiency. Best combined with exercise for fat loss benefits. | Phase 2 (subcutaneous): doses of 2.5, 5, 10, and 15 mg once weekly with stepwise escalation. The 15 mg arm produced the maximum weight loss of 14.7% at 13 weeks. Oral formulation in Phase 1: 30-100 mg daily, dose escalation ongoing. |
| Administration | Oral (capsule, liquid) or intramuscular injection | Subcutaneous injection (once weekly); oral tablet formulation in earlier development |
| Research Papers | 30 papers | 1 papers |
| Categories |
Mechanism of Action
L-Carnitine
L-Carnitine plays an indispensable role in cellular energy metabolism as the sole carrier molecule for transporting long-chain fatty acids (14+ carbons) across the inner mitochondrial membrane, which is otherwise impermeable to them. This transport system, known as the carnitine shuttle, is the rate-limiting step for fatty acid beta-oxidation — without carnitine, long-chain fats simply cannot be burned for energy.
The shuttle operates through a three-enzyme system. First, carnitine palmitoyltransferase I (CPT-I), located on the outer mitochondrial membrane, conjugates carnitine to a fatty acyl-CoA molecule, forming acylcarnitine. This acylcarnitine crosses the inner membrane via the carnitine-acylcarnitine translocase (CACT). Inside the mitochondrial matrix, carnitine palmitoyltransferase II (CPT-II) releases the fatty acid (as acyl-CoA) for beta-oxidation while regenerating free carnitine, which shuttles back out. Each cycle of beta-oxidation cleaves two carbons from the fatty acid chain, producing acetyl-CoA (which enters the citric acid cycle), FADH2, and NADH — generating substantial ATP.
Beyond fat transport, L-carnitine serves additional metabolic functions. It buffers the acyl-CoA/CoA ratio in cells, preventing toxic accumulation of acyl-CoA intermediates. It supports branched-chain amino acid metabolism and may improve mitochondrial function in aging tissues. In people with genuine carnitine deficiency (genetic or dialysis-related), supplementation produces dramatic improvements in energy and fat metabolism. However, in individuals with normal carnitine levels, supplementation has shown more modest effects, as the carnitine shuttle is rarely the limiting factor when carnitine is already adequate.
VK2735
VK2735 is a once-weekly subcutaneous dual GLP-1/GIP receptor agonist with a structure optimised for high potency and a clean tolerability profile. Dual incretin receptor activation produces complementary effects on appetite, glucose handling, and energy expenditure: GLP-1 receptor agonism delivers central appetite suppression through hypothalamic arcuate-nucleus signalling, slows gastric emptying, and triggers glucose-dependent insulin secretion, while GIP receptor activation amplifies the insulin response, supports beta-cell function, and modulates adipose tissue lipid handling.
The molecule's pharmacokinetic profile delivers sustained receptor exposure across a one-week dosing interval, achieved through structural modifications that enable albumin binding and resistance to proteolytic degradation. In the Phase 2 VENTURE trial, the 15 mg dose produced 14.7% mean body weight loss at 13 weeks — the fastest early weight loss observed for any obesity drug, with the loss curve still descending steeply at trial end. This rapid trajectory suggests substantially greater total weight loss would be achievable with longer dosing, and Phase 3 VANQUISH trials launched in 2026 are testing 68-week treatment durations to characterise the full magnitude of effect.
Viking is also developing an oral tablet formulation of VK2735 in parallel, which entered Phase 1 in 2024-2025. If both formulations succeed, Viking would have one of the most flexible GLP-1/GIP product profiles on the market — though as a small biotech company it faces significant manufacturing and commercial scaling challenges relative to Lilly and Novo Nordisk.
Risks & Safety
L-Carnitine
Common
nausea, diarrhea, stomach cramps, fishy body odour at high oral doses.
Serious
chronic high-dose oral use may produce TMAO, a compound linked to heart disease risk.
Rare
seizures in people with pre-existing seizure disorders.
VK2735
Common
nausea, vomiting, diarrhea, constipation, decreased appetite, injection site reactions. Discontinuation rates in Phase 2 were broadly similar to other GLP-1/GIP dual agonists.
Serious
pancreatitis, gallstones, possible muscle mass loss.
Rare
thyroid C-cell tumour class warning, severe allergic reactions. Long-term safety being established in Phase 3.
Full Profiles
L-Carnitine →
A natural substance your body already makes that acts as a 'shuttle' to carry fat into your cells' energy factories (mitochondria) where it gets burned for fuel. Without enough carnitine, your body literally cannot burn long-chain fats for energy. One of the most popular and well-studied fat metabolism supplements available. Has FDA-approved forms for people with carnitine deficiency, and is widely available over the counter as a supplement.
VK2735 →
Viking Therapeutics' once-weekly weight loss injection that, like tirzepatide, hits both the GLP-1 and GIP receptors. In a 13-week Phase 2 trial it produced 14.7% mean body weight loss — the steepest early loss curve recorded for any obesity drug — and Phase 3 VANQUISH trials began in 2026. An oral tablet version is also in earlier development. Viking is one of the only small biotech companies competing directly with Lilly and Novo Nordisk in the GLP-1 space.